Breast Cancer Update Course (BCU) - Part II
6 ESCO credits
03.05.2014 - 04.05.2014
Milan
COURSES AND SEMINARS
Description
Chairs: M. Aapro, CH - F. Cardoso, PT - H.S. Rugo, US
Within the 2014 educational offer and following the first part of the Breast Cancer Update (BCU) course held in Lisbon, Portugal on 9 and 10 November 2013, ESO is establishing the second part of this high-level course on breast cancer tailored for trained oncologists in all disciplines with the aim to provide an update on the state-of-the-art therapeutic options as well as an overview of the latest advances in the field. As in the first part of the event, the programme will be designed with plenary lectures as well as meet-the-professor group sessions offering balanced and blended educational contents.
Further to the first part of the BCU course, the format will be developed with:
• the organisation of a tumour board discussion;
• the discussion of clinical cases presented by the participants.
LEARNING OBJECTIVES
• Update on the state-of-the-art therapeutic options
• Provide an overview of the latest advances in the field
• Strengthen leadership skills
• Improve presentation skills
• Debate controversies and challenges in breast cancer treatment
MAIN TOPICS
• Advances in breast cancer: Key messages in 2014
• Progress in supportive care
• From science to clinical practice
• Leadership skills
• Presentation skills
• Controversies and challenges in breast cancer treatment
• The voice of the patient
• Meet-the-expert, breakout sessions
Within the 2014 educational offer and following the first part of the Breast Cancer Update (BCU) course held in Lisbon, Portugal on 9 and 10 November 2013, ESO is establishing the second part of this high-level course on breast cancer tailored for trained oncologists in all disciplines with the aim to provide an update on the state-of-the-art therapeutic options as well as an overview of the latest advances in the field. As in the first part of the event, the programme will be designed with plenary lectures as well as meet-the-professor group sessions offering balanced and blended educational contents.
Further to the first part of the BCU course, the format will be developed with:
• the organisation of a tumour board discussion;
• the discussion of clinical cases presented by the participants.
LEARNING OBJECTIVES
• Update on the state-of-the-art therapeutic options
• Provide an overview of the latest advances in the field
• Strengthen leadership skills
• Improve presentation skills
• Debate controversies and challenges in breast cancer treatment
MAIN TOPICS
• Advances in breast cancer: Key messages in 2014
• Progress in supportive care
• From science to clinical practice
• Leadership skills
• Presentation skills
• Controversies and challenges in breast cancer treatment
• The voice of the patient
• Meet-the-expert, breakout sessions
General information
TRAVEL GRANTS
Travel grants will be made available to all participants.
The following amounts will be refunded by bank transfer after the course: EUR 100 for participants coming from Italy; EUR 250 for participants coming from Southern Europe; EUR 400 for participants coming from Northern Europe; EUR 500 for participants coming from other regions. **
**Please refer to the UN geographical region and composition: http://unstats.un.org/unsd/methods/m49/m49regin.htm#europe
ORGANISING SECRETARIAT
European School of Oncology
Via Turati, 29
20121 Milan, Italy
www.eso.net
Programme and Organisation
Francesca Marangoni
E-mail: fmarangoni@eso.net
Ph: +39 02 85464525
+39 02 85464525
Participants
Elena Fiore
E-mail: efiore@eso.net
Ph: +39 02 85464529+39 02 85464529
OFFICIAL LANGUAGE
The official language will be English. No translation will be provided.
ACCREDITATION
Application for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).
Information on the status of the applications can be obtained from the organising secretariat.
INSURANCE
The organisers bear no responsibility for untoward events in relation to the participation in the course. Participants are advised to take out their own personal and travel insurance coverage.
SHARING PROGRESS IN CANCER CARE
Sharing Progress in Cancer Care programme (SPCC) is a pioneering partnership between the European School of Oncology and some of the world’s leading pharmaceutical companies.
This programme is organised through unrestricted grants provided by Novartis Oncology and Genomic Health, sustaining members of the SPCC programme.
Faculty list
FACULTY
M. Aapro, Clinique de Genolier, Oncology Dpt., Genolier, CH
F.A. Calvo, Hospital General Universitario Gregorio Marañon, Dept. of Oncology, Madrid, ES
F. Cardoso, Champalimaud Cancer Center, Breast Unit, Lisbon, PT
M.J. Cardoso, Champalimaud Cancer Center, Breast Unit, Lisbon, PT
V. Dieras, Institut Curie, Oncology Dept., Paris, FR
N. El Saghir, American University of Beirut Medical Center, Naef K. Basile Cancer Center, Beirut, LB
J. Gligorov, Hopitaux Universitaires Paris Est Tenon, Dept. of Medical Oncology, Paris, FR
N. Harbeck, Hospital of the University of Munich (LMU), Breast Centre, Dept. fo Obstetrics and Gynaecology, Munich, DE
O. Pagani, Oncology Institute of Southern Switzerland (IOSI), Breast Unit, Bellinzona, CH
H.S. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, Breast Oncology Clinical Trials Education, San Francisco, US
Programme
3 May
12:30 | Arrivals, registrations and lunch | |
| 13.45 | Opening M. Aapro, CH - F. Cardoso, PT - H.S. Rugo, US | |
14:00 | Introduction: practice changing news from San Antonio and EBCC H.S. Rugo, US - F. Cardoso, PT | |
| 14:30 | Application of new data to low income countries (when resources are limited), BGH guidelines N. El Saghir, LB | |
| 14:50 | Panel discussion | |
| 15:00 | HER2 positive disease: Optimal neoadjuvant vs adjuvant therapy, what to do when patients have residual disease following neoadjuvant therapy | |
| 15:30 | Progress in radiation techniques: Early stage therapy, Peri or intraoperative/hypofractionation, New techniques for treating metastatic disease F. Calvo, ES | |
| 16:00 | Coffee break | |
| 16:30 | Meet-the-expert, breakout sessions 1 (4 groups, 2 topics) | |
| 17:30 | New cytotoxic agents for the treatment of breast cancer, what is the optimal sequencing/schedules of agents for advanced disease O. Pagani, CH | |
| 18:00 | Current and future targeted agents for HR+ BrCA, optimal sequencing N. Harbeck, DE | |
| 18:30 | Close | |
| 19:30 | Group dinner | |
4 May
8:30 | Application of genomic tests to local therapy decisions | |
9:00 | Tumour board on clinical cases | |
10:00 | Progress in surgery | |
| 10:30 | Coffee break | |
| 11:00 | Meet-the-expert, breakout sessions 2 (4 groups, 2 topics) | |
| 12:00 | Lunch | |
| 13:00 | Patient cases to be brought by participants, focused on some of the presented topics: HER2+ adjuvant/neoadjuvant, reconstruction | |
| 14:00 | Depending on suggestions from BCU I - Topics, Cases, Controversies | |
| 14:30 | Cooperative/consortium group trials : is the era of large trials over? Trials/treatment based on subtype? N. Harbeck | |
| 15:30 | Close |